Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) Short Interest Down 7.2% in December

Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) was the recipient of a large decline in short interest during the month of December. As of December 15th, there was short interest totalling 43,800 shares, a decline of 7.2% from the November 30th total of 47,200 shares. Based on an average daily trading volume, of 43,700 shares, the short-interest ratio is currently 1.0 days. Approximately 0.6% of the company’s shares are sold short.

Hepion Pharmaceuticals Stock Down 3.7 %

HEPA traded down $0.02 during trading on Monday, reaching $0.44. 45,633 shares of the stock traded hands, compared to its average volume of 79,167. The stock’s 50-day moving average is $0.62 and its 200 day moving average is $0.74. Hepion Pharmaceuticals has a 12 month low of $0.44 and a 12 month high of $3.49. The stock has a market capitalization of $3.08 million, a PE ratio of -0.10 and a beta of 1.63.

Hedge Funds Weigh In On Hepion Pharmaceuticals

An institutional investor recently raised its position in Hepion Pharmaceuticals stock. Armistice Capital LLC lifted its position in shares of Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) by 32.3% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 516,000 shares of the company’s stock after purchasing an additional 126,000 shares during the quarter. Armistice Capital LLC owned 9.43% of Hepion Pharmaceuticals worth $526,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 17.24% of the company’s stock.

About Hepion Pharmaceuticals

Hepion Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms.